MDWD
MediWound Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$13.40
+0.37%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$13.42
From 52W high−31.95%
Volume81943.00
Market cap$173.00M
P/E (TTM)—
P/S (TTM)14.6x
Div yield—
Key dataSep 18, 2026
Open
$13.42
From 52W high
−31.95%
Volume
81943.00
Market cap
$173.00M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.7x
P/E (TTM)
—
RSI (14)
47.9
MomentumView details →
1D Return
+0.37%
YTD Return
−27.95%
SummaryUpdated Jun 1, 2026
MediWound Ltd. (NASDAQ:MDWD) is an Israeli biopharmaceutical company founded in 2000 and headquartered in Yavne, Israel. The company went public on NASDAQ in March 2014. MediWound specializes in developing, manufacturing, and commercializing novel enzymatic bio-therapeutic solutions for tissue repair and regeneration, with a primary focus on wound debridement - the medical process of removing dead, damaged, or infected tissue to promote healing.
Similar companies
Latest newsMore news →
MediWound announced that the independent Data and Safety Monitoring Board completed a pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended the study continue without modification.6d agoMediWound reported a Q2 2026 net loss of $0.77 per share, compared to a loss of $1.23 per share a year ago.38d ago